Top

Clinical and Translational Oncology

Published in:

01-07-2013 | Research Article

Upregulation of microRNA-224 confers a poor prognosis in glioma patients

Authors: S. Lu, S. Wang, S. Geng, S. Ma, Z. Liang, B. Jiao

Published in: Clinical and Translational Oncology | Issue 7/2013

Abstract

Objective

MicroRNA-224 (miR-224) has been consistently reported to be dysregulated in various human malignancies and can potentially affect many cancer-related cellular processes, including transcription, cell differentiation, cell death, growth, and cell proliferation. However, its roles in human glioma have not been reported. The aim of this study was to explore the expression pattern, clinical significance, and prognostic value of miR-224 in glioma patients using large cohorts.

Methods

Quantitative real-time polymerase chain reaction analysis was used to characterize the expression patterns of miR-224 in 108 glioma and 20 normal brain tissues. The associations of miR-224 expression with clinicopathological factors and prognosis of glioma patients were also statistically analyzed.

Results

miR-224 expression is significantly upregulated in glioma tissues compared with normal brain tissues (P < 0.001). In addition, high expression of miR-224 was significantly associated with advanced pathological grade (P = 0.006) and low Karnofsky performance score (KPS, P = 0.01). Moreover, Kaplan–Meier survival analysis showed that high miR-224 expression group had significantly shorter disease-free survival (DFS) and overall survival (OS) rates than low miR-224 expression group (both P < 0.001). Multivariate analysis with the Cox’s proportional hazards model revealed that high expression of miR-224 (P = 0.006 and P = 0.01, respectively) and advanced pathological grade (both P = 0.02) were independent factors for shorter DFS and OS. Furthermore, subgroup analyses showed that miR-224 expression was significantly associated with poor DFS and OS in glioma patients with high pathological grades (for grade III–IV: P < 0.001 and P = 0.005, respectively).

Conclusions

MiR-224 is upregulated and confers a poor prognosis in glioma patients.

Rousseau A, Mokhtari K, Duyckaerts C (2007) The 2007 WHO classification of tumors of the central nervous system-what has changed? Curr Opin Neurol 21:720–727CrossRef

Brandes AA (2003) State-of-the-art treatment of high-grade brain tumors. Semin Oncol 30:4–9PubMedCrossRef

Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109:93–108PubMedCrossRef

Hutterer M, Knyazev P, Abate A (2008) Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res 14:130–138PubMedCrossRef

Visone R, Croce CM (2009) MiRNAs and cancer. Am J Pathol 174:1131–1138PubMedCrossRef

Liu A, Xu X (2011) MicroRNA isolation from formalin-fixed, paraffin embedded tissues. Methods Mol Biol 724:259–267PubMedCrossRef

Chan XH, Nama S, Gopal F, Rizk P, Ramasamy S, Sundaram G, Ow GS, Vladimirovna IA, Tanavde V, Haybaeck J, Kuznetsov V, Sampath P (2012) Targeting glioma stem cells by functional inhibition of a prosurvival OncomiR-138 in malignant gliomas. Cell Rep 2:591–602

Papagiannakopoulos T, Shapiro A, Kosik KS (2008) MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 68:8164–8172PubMedCrossRef

Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A, Nuovo G, Raychaudhury A, Newton HB, Chiocca EA, Lawler S (2008) Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 68:9125–9130PubMedCrossRef

10.

Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E (2009) MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer 125:1407–1413PubMedCrossRef

11.

Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, Araki Y, Kuga D, Nakamizo A, Amano T, Ma X, Hayashi K, Sasaki T (2010) MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res 16:4289–4297PubMedCrossRef

12.

Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research Network (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110PubMedCrossRef

13.

Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A, Brownstein MJ, Tuschl T, Margalit H (2005) Clustering and conservation patterns of human microRNAs. Nucleic Acids Res 33:2697–2706PubMedCrossRef

14.

Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, Chiaretti S, Foa R, Schliwka J, Fuchs U, Novosel A, Muller RU, Schermer B, Bissels U, Inman J, Phan Q, Chien M (2007) A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129:1401–1414PubMedCrossRef

15.

Wang Y, Lee CG (2011) Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention? Epigenomics 3:235–243PubMedCrossRef

16.

Fu J, Tang W, Du P, Wang G, Chen W, Li J, Zhu Y, Gao J, Cui L (2012) Identifying microRNA-mRNA regulatory network in colorectal cancer by a combination of expression profile and bioinformatics analysis. BMC Syst Biol 6:68PubMedCrossRef

17.

Gokhale A, Kunder R, Goel A, Sarin R, Moiyadi A, Shenoy A, Mamidipally C, Noronha S, Kannan S, Shirsat NV (2010) Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway. J Cancer Res Ther 6:521–529PubMedCrossRef

18.

Pai R, Nehru GA, Samuel P, Selvan B, Kumar R, Jacob PM, Nair A (2012) Discriminating thyroid cancers from benign lesions based on differential expression of a limited set of miRNA using paraffin embedded tissues. Indian J Pathol Microbiol 55:158–162PubMedCrossRef

19.

Mees ST, Mardin WA, Sielker S, Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M, Haier J (2009) Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol 16:2339–2350PubMedCrossRef

20.

Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM, Yfantis HG, Lee DH, Stephens RM, Liu CG, Calin GA, Croce CM, Ambs S (2008) Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate 68:1152–1164PubMedCrossRef

21.

Lichner Z, Mejia-Guerrero S, Ignacak M, Krizova A, Bao TT, Girgis AH, Youssef YM, Yousef GM (2012) Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways. Am J Pathol 180:1675–1687PubMedCrossRef

22.

Christenson LK (2010) MicroRNA control of ovarian function. Anim Reprod 7:129–133PubMed

23.

Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M, Carinci F (2010) MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol 23:1229–1234PubMed

24.

Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, Tantoso E, Li KB, Ooi LL, Tan P, Lee CG (2008) Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 283:13205–13215PubMedCrossRef

25.

Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N, Bentwich Z, Hod M, Goren Y, Chajut A (2008) Serum microRNAs are promising novel biomarkers. PLoS ONE 3:e3148PubMedCrossRef

26.

Li X, Shen Y, Ichikawa H, Antes T, Goldberg GS (2009) Regulation of miRNA expression by Src and contact normalization: effects on nonanchored cell growth and migration. Oncogene 28:4272–4283PubMedCrossRef

27.

Huang L, Dai T, Lin X, Zhao X, Chen X, Wang C, Li X, Shen H, Wang X (2012) MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells. Biochem Biophys Res Commun 425:127–133PubMedCrossRef

Title: Upregulation of microRNA-224 confers a poor prognosis in glioma patients
Authors: S. Lu
S. Wang
S. Geng
S. Ma
Z. Liang
B. Jiao
Publication date: 01-07-2013
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 7/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0972-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2013

Management and outcome of ovarian malignancy complicating pregnancy: an analysis of 41 cases and review of the literature

GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012

Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis

Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients

Altered expression of piRNAs and their relation with clinicopathologic features of breast cancer

Should be NICE have a Spanish NICE?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer